non-peptide: the version I wish someone had shown me in week 1
non-peptide: the version I wish someone had shown me in week 1. Posting the boring middle of the process, because the internet is full of the start and the end and nothing else.
Spent an evening reading about small-molecule agonism at a peptide receptor. Genuinely interesting engineering.
Daily rather than weekly sounds trivial until you think about what a missed dose means in each case.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
Because it is not a peptide, it is not subject to the same degradation pathways, does not require the absorption enhancers used for oral peptides, and can be formulated as a conventional tablet.
Compared milligram figures across two completely different molecule classes in a comment. Deserved the correction.
Compared milligram figures across two completely different molecule classes in a comment.
Disagreeing with this bit: daily dosing is a different adherence problem, not a better one.
nothing containing this is approved anywhere and research material is not for human use
It is a non-peptide small-molecule agonist at the GLP-1 receptor. That is a substantial medicinal chemistry achievement: getting a small molecule to activate a receptor evolved for a peptide ligand.
phase 3 is where the comparison becomes fair
the boards keep comparing it to injectables at matched doses, which is meaningless
Disagree. You are comparing doses across a small molecule and a peptide, which is not a comparison of anything.
The no-timing-restriction thing is the part I would care about most in practice, and it barely gets mentioned here.
What is actually known, and what is being assumed.
Known: it is a small-molecule GLP-1 receptor agonist, dosed daily, with clinical programmes reporting in both obesity and type 2 diabetes. Its tolerability profile broadly resembles the class in the data published so far.
Assumed, frequently and confidently: that milligram comparisons with injectables mean something, that adherence is straightforwardly better because it is a tablet, that peptide purity discussions transfer to it. None of those hold. And nothing containing this compound is approved anywhere, which makes research-use-only material exactly that — not approved for human use.
Left up. It is careful about what is peptide and what is not, which is more than most threads here manage.
Read both programme names carefully after mixing them up in a comment and being politely corrected.
the tolerability profile reads broadly similar to the class
oral semaglutide is a peptide with an absorption enhancer, this is not that
daily dosing, not weekly, so the exposure profile is different
Cosigning on daily dosing. It changes the exposure profile and it changes adherence, in both directions.
Daily dosing, so what does the exposure profile look like across the day?
- 1Because it is not a peptide, it is not subject to the same degradation…7 comments in this branch · started by u/farid_kuipers